---
layout: post
title: New Drug Approvals 2013 - Pt. VIII - Fluticasone furoate and Vilanterol (Breo
  ElliptaTM)
date: '2013-05-26T08:02:00.002+01:00'
author: Rita
tags:
- Small Molecule Drugs
- 2013 New Drugs
- Topical Drugs
- Black Box Warning Drugs
- Combination Drugs
modified_time: '2013-05-26T08:03:12.102+01:00'
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8588205995110266388
blogger_orig_url: http://chembl.blogspot.com/2013/05/new-drug-approvals-2013-pt-viii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.trademarkia.com/logo-images/500323-company/breo-ellipta-85826011.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="132" src="http://www.trademarkia.com/logo-images/500323-company/breo-ellipta-85826011.jpg" width="320" /></a></div>
<br />
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,0,0,1,1,1" width="400" /></center>
<br />
<div style="text-align: center;">
<b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=R03AK10">R03AK10</a><br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Vilanterol">Vilanterol</a><br />
<br /></div>
<div style="text-align: justify;">
On May 10<sup>th</sup>, the FDA approved Vilanterol (Tradename: <a href="http://www.trademarkia.com/breo-ellipta-85826011.html">Breo Ellipta</a>; Research Code: GW-642444M), a <a href="http://en.wikipedia.org/wiki/Long-acting_beta-adrenoceptor_agonist">long-acting beta<sub>2</sub>-adrenergic agonist</a>, in combination with the already approved <a href="http://en.wikipedia.org/wiki/Fluticasone_furoate">fluticasone furoate</a>, an inhaled <a href="http://en.wikipedia.org/wiki/Corticosteroid">corticosteroid</a>, for the long-term maintenance treatment of <a href="http://en.wikipedia.org/wiki/Bronchospasm">bronchospasm</a> associated with <a href="http://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease">chronic obstructive pulmonary disease</a> (COPD).</div>
<br />
<div style="text-align: justify;">
Chronic obstructive pulmonary disease (COPD) is characterised by the occurrence of <a href="http://en.wikipedia.org/wiki/Chronic_bronchitis">chronic bronchitis</a> or <a href="http://en.wikipedia.org/wiki/Emphysema">emphysema</a>, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. Bronchial spasms, a sudden constriction of the muscles in the walls of the <a href="http://en.wikipedia.org/wiki/Bronchiole">bronchioles</a>, occur frequently in COPD.</div>
<br />
<div style="text-align: justify;">
Vilanterol is a new long-acting beta<sub>2</sub>&nbsp;receptor agonist that through the activation of the beta<sub>2</sub> adrenergic receptors present in the bronchial smooth muscle, leads to bronchodilation, and consequently eases the symptoms of COPD.</div>
<br />
<div style="text-align: justify;">
The beta<sub>2</sub> adrenergeic receptor (Uniprot: <a href="http://www.uniprot.org/uniprot/P07550">P07550</a>; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL210">CHEMBL210</a>) belongs to the G-protein coupled receptor (GPCR) type 1 family, and binds the endogenous neurotransmitter <a href="https://en.wikipedia.org/wiki/Epinephrine">adrenaline</a>. Since it is coupled to a Gs protein, its activation leads ultimately to an increase in <a href="http://en.wikipedia.org/wiki/Cyclic_adenosine_monophosphate">cyclic AMP</a> (cAMP), which cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.<br />
<br />
<pre>&gt;ADRB2_HUMAN Beta-2 adrenergic receptor
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS
IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE
AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF
HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD
NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT
GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
</pre>
<br />
There are 11 resolved 3D structures for this protein with vary degrees of resolution (2.40 to 3.50 &amp;#197) and different fusion protocols. For instance, <a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/3ny8/summary">3ny8</a>, is a fused protein of the human beta<sub>2</sub> adrenergeic receptor with Lysozyme Bacteriophage T4, with a resolution of 2.84 &amp;#197 and an inverse agonist bound to it (<a href="http://en.wikipedia.org/wiki/ICI-118,551">ICI-118,551</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL513389">CHEMBL513389</a>):<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.ebi.ac.uk/pdbe-apps/widgets/PDBimages/ny/38/full5.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="300" src="http://www.ebi.ac.uk/pdbe-apps/widgets/PDBimages/ny/38/full5.png" width="400" /></a></div>
<br />
The full list of PDBe entries can be found <a href="http://www.ebi.ac.uk/pdbe/searchResults.html?display=pdb&amp;search_type=advanced&amp;sort_column=reverse_release_date&amp;Uniprot=P07550&amp;term=UniProt:%20P07550">here</a>.</div>
<br />
<div style="text-align: justify;">
The -terol USAN/INN stem covers bronchodilators structurally related with <a href="http://en.wikipedia.org/wiki/Phenethylamine">phenethylamine</a>. Members of these class include for example <a href="http://en.wikipedia.org/wiki/Salmeterol">Salmeterol</a> (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1263">CHEMBL1263</a>), <a href="http://en.wikipedia.org/wiki/Formoterol">Formoterol</a> (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1256786">CHEMBL1256786</a>) and <a href="http://chembl.blogspot.co.uk/2011/07/new-drug-approvals-2011-pt-xxii.html">Indacaterol</a> (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1095777">CHEMBL1095777</a>), all long-acting beta<sub>2</sub>-adrenergic agonists also approved for the management of COPD. For a full list of compounds check <a href="https://www.ebi.ac.uk/chembldb/drugstore#">ChEMBL</a>.</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembldb/compound/displayimage_large/672807" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://www.ebi.ac.uk/chembldb/compound/displayimage_large/672807" width="320" /></a></div>
<br />
<div style="text-align: justify;">
Vilanterol (IUPAC Name: 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Canonical smiles: OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1198857">CHEMBL1198857</a>; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10184665">10184665</a>; ChemSpider: <a href="https://www.chemspider.com/Chemical-Structure.8360167.html">8360167</a>; Standard InChI Key: DAFYYTQWSAWIGS-DEOSSOPVSA-N) is a synthetic small molecule, with a molecular weight of 486.4 Da, 6 hydrogen bond acceptors, 4 hydrogen bond donors, and has an ALogP of 4.22. The compound is therefore fully compliant with the rule of five.</div>
<br />
<div style="text-align: justify;">
Breo Ellipta is available as a dry powder inhaler and the recommended daily dose is one inhalation of fluticasone furoate/vilanterol 100/25 mcg. Following inhalation, vilanterol peak plasma concentrations are reached within 10 minutes, and its absolute bioavailability is 27.3%. At steady state, following intravenous administration, the mean volume of distribution of vilanterol (Vd/F) was 165L in healthy subjects. Vilanterol is strongly bound to human plasma proteins (93.3 %). <br />
<br />
Vilanterol is primarily metabolized in the liver by CYP3A4. Therefore, concomitant administration of potent CYP3A4 inhibitors should be avoided. Vilanterol metabolites are primarily excreted in urine (70%) and feces (30%). The effective half-life (t<sub>1/2</sub>) for Vilanterol is approximately 21 hours in patients with COPD.</div>
<br />
<div style="text-align: justify;">
Breo Ellipta has been issued with a black box warning due to Vilanterol increased risk of asthma-related death, a known risk to all long-acting beta<sub>2</sub>-adrenergic agonists. </div>
<br />
<div style="text-align: justify;">
The license holder for Breo Ellipta<sup>TM</sup> is <a href="http://www.blogger.com/www.gsk.com">GlaxoSmithKline</a>, and the full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204275s000lbl.pdf">here</a>.</div>
